Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

77 New Cases of Hepatitis Are Identified in Las Vegas
at 4:52 a.m. Nevada health officials said Thursday that they had identified 77 new cases of hepatitis C among patients treated at a Las Vegas endoscopy practice, in one of the countrys largest outbreaks of the liver disease. The officials had previously

Risk of Malignant Lymphoma Increased With Hepatitis C Infection
Extract not available.

77 New Cases of Hepatitis Are Identified in Las Vegas
Nevada health officials said Thursday that they had identified 77 new cases of hepatitis C among patients treated at a Las Vegas endoscopy practice, in one of the countrys largest outbreaks of the liver disease. The officials had previously identified


UPDATES AND COMMENTARY RSS Feed

Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...

Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...

Hepatitis C Complications Helped by Maintenance Interferon
A four-year study confirms that low-dosage maintenance interferon therapy prevents disease progression in those with portal hypertension or cirrhosis from Hepatitis C....

New Warnings Placed On Rebetron Hepatitis Therapy

PHILADELPHIA, PA -- Feb. 18, 1999 -- After just six months on the market, revised safety information tells doctors and patients to be even more cautious in the use of combination therapy to treat hepatitis C.

A black box warning in the revised prescribing information for Schering-Plough’s Rebetron(TM) warns that patients and their partners must use two forms of contraception because of the risk of birth defects or loss of a pregnancy from combination therapy.

Even if only one partner is taking Rebetron, both members of the couple need to use adequate contraception during therapy and for six months after the end of treatment.

Rebetron is a combination of Rebetol(R) (ribavirin, USP) Capsules and Intron(R) A (interferon alfa-2b, recombinant) Injection. It is the ribavirin component that is blamed for the risks to the fetus.

The United States Food and Drug Administration recently approved Rebetron combination therapy for patients with hepatitis C who had never been treated before. Previously, only people who had failed a previous treatment could receive Rebetron. But at the same time as it allowed wider use, the FDA increased the warnings to reflect the danger of the combination therapy during pregnancy. Ever since Rebetron was first approved, Schering-Plough has maintained a registry to track people on the therapy who become pregnant.

Dr. Enrique Molina, a hepatologist and assistant professor of clinical medicine at the Center for Liver Diseases, University of Miami, FL., says no patients with pregnancy-related complications from Rebetron treatment have been referred to his practice yet. However, he feels physicians need to counsel patients carefully before prescribing Rebetron.

"If a patient is not willing to practice strict contraception, that's certainly a contraindication for ribavirin. It makes a bigger difference for younger patients than for older ones," he said. "Many of our patients are 40 or 50 and already practising contraception so it's not a big issue for them, but for those that are younger, it's definitely an important point for physicians to stress."

table Of Contents

Hepatitis Central

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 09 May 2008